Barclays PLC Iovance Biotherapeutics, Inc. Transaction History

Barclays PLC

  • $377 Billion
  • Q3 2024

A detailed history of Barclays PLC transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Barclays PLC holds 604,584 shares of IOVA stock, worth $5.17 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
604,584
Previous 604,584 -0.0%
Holding current value
$5.17 Million
Previous $5.68 Million -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024
BUY
$7.28 - $11.9 $2.39 Million - $3.91 Million
328,284 Added 118.81%
604,584 $5.68 Million
Q2 2024

Aug 14, 2024
BUY
$7.78 - $14.19 $162,967 - $297,237
20,947 Added 8.2%
276,300 $2.22 Million
Q1 2024

May 15, 2024
SELL
$7.59 - $17.47 $4.41 Million - $10.1 Million
-580,822 Reduced 69.46%
255,353 $3.78 Million
Q4 2023

Feb 15, 2024
BUY
$3.3 - $8.89 $258,139 - $695,411
78,224 Added 10.32%
836,175 $6.8 Million
Q3 2023

Nov 07, 2023
BUY
$4.44 - $8.79 $1.01 Million - $2.01 Million
228,359 Added 43.12%
757,951 $3.45 Million
Q2 2023

Aug 03, 2023
BUY
$5.36 - $9.06 $602,635 - $1.02 Million
112,432 Added 26.95%
529,592 $3.73 Million
Q1 2023

May 04, 2023
SELL
$5.53 - $8.22 $1.18 Million - $1.76 Million
-213,790 Reduced 33.88%
417,160 $2.55 Million
Q4 2022

Feb 13, 2023
BUY
$5.62 - $10.0 $1.35 Million - $2.4 Million
240,344 Added 61.53%
630,950 $4.03 Million
Q3 2022

Nov 03, 2022
BUY
$9.53 - $13.11 $3.31 Million - $4.55 Million
347,191 Added 799.7%
390,606 $3.74 Million
Q2 2022

Aug 12, 2022
SELL
$6.38 - $18.33 $190,436 - $547,132
-29,849 Reduced 40.74%
43,415 $479,000
Q1 2022

May 16, 2022
BUY
$12.38 - $19.1 $833,322 - $1.29 Million
67,312 Added 1130.91%
73,264 $1.22 Million
Q4 2021

Feb 14, 2022
SELL
$16.55 - $27.63 $412,723 - $689,036
-24,938 Reduced 80.73%
5,952 $114,000
Q3 2021

Nov 09, 2021
SELL
$20.35 - $26.63 $1.21 Million - $1.58 Million
-59,373 Reduced 65.78%
30,890 $761,000
Q2 2021

Aug 13, 2021
BUY
$16.33 - $33.07 $357,120 - $723,207
21,869 Added 31.98%
90,263 $2.35 Million
Q1 2021

May 13, 2021
BUY
$28.67 - $52.59 $52,208 - $95,766
1,821 Added 2.74%
68,394 $2.17 Million
Q4 2020

Feb 11, 2021
BUY
$28.04 - $50.26 $213,580 - $382,830
7,617 Added 12.92%
66,573 $3.09 Million
Q3 2020

Nov 12, 2020
SELL
$27.75 - $36.3 $3.7 Million - $4.84 Million
-133,423 Reduced 69.35%
58,956 $1.94 Million
Q2 2020

Aug 12, 2020
BUY
$27.21 - $41.0 $1.92 Million - $2.89 Million
70,563 Added 57.93%
192,379 $5.28 Million
Q1 2020

May 13, 2020
SELL
$19.54 - $38.85 $1.72 Million - $3.41 Million
-87,865 Reduced 41.9%
121,816 $3.65 Million
Q4 2019

Feb 10, 2020
BUY
$17.95 - $29.41 $1.87 Million - $3.06 Million
104,169 Added 98.73%
209,681 $5.8 Million
Q3 2019

Nov 14, 2019
BUY
$17.99 - $26.0 $550,098 - $795,028
30,578 Added 40.81%
105,512 $1.92 Million
Q2 2019

Aug 14, 2019
BUY
$9.78 - $24.52 $184,900 - $463,575
18,906 Added 33.74%
74,934 $1.84 Million
Q1 2019

May 15, 2019
BUY
$8.41 - $11.26 $471,195 - $630,875
56,028 New
56,028 $534,000
Q4 2018

Feb 14, 2019
SELL
$7.51 - $11.93 $359,428 - $570,969
-47,860 Closed
0 $0
Q3 2018

Nov 14, 2018
BUY
$11.25 - $17.7 $392,017 - $616,774
34,846 Added 267.76%
47,860 $539,000
Q2 2018

Aug 14, 2018
SELL
$12.45 - $16.95 $52,875 - $71,986
-4,247 Reduced 24.6%
13,014 $167,000
Q1 2018

May 15, 2018
SELL
$8.1 - $19.5 $150,157 - $361,491
-18,538 Reduced 51.78%
17,261 $291,000
Q4 2017

Feb 14, 2018
BUY
$6.65 - $9.25 $216,543 - $301,207
32,563 Added 1006.27%
35,799 $286,000
Q3 2017

Nov 14, 2017
BUY
$4.45 - $8.55 $14,400 - $27,667
3,236
3,236 $25,000

Others Institutions Holding IOVA

# of Institutions
314
Shares Held
241M
Call Options Held
3.77M
Put Options Held
1.7M
View Full List

About IOVANCE BIOTHERAPEUTICS, INC.

IOVA Quotes by TradingView
  • Ticker IOVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 157,800,992
  • Market Cap $1.35B
  • Description
  • Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...
More about IOVA
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email